Pfizer names Cecile Guegan chief financial officer, effective November 1, 2026

Pfizer's board of directors unanimously elected Cecile Guegan as chief financial officer and executive vice president, effective November 1, 2026. The company announced the election on November 3, 2026.

Guegan has more than 25 years of global finance leadership in the pharmaceutical industry. She joined Pfizer in connection with its 2009 acquisition of Wyeth, where she had been chief financial officer supporting the Asia Pacific and EMEA/Canada businesses. At Pfizer, she has held finance leadership roles across Oncology, Research and Development, and the Global Biopharmaceuticals Group.

Pfizer said Guegan will oversee all corporate finance functions, including audit, treasury, investor relations, tax, insurance, operations planning and analysis, corporate controllership, and business finance and analytics.

The Compensation Committee of the board unanimously approved compensation for Guegan as of the effective date. Her annual base salary is $1.3 million. Pfizer said Guegan's annual target cash incentive opportunity is $1.3 million, equal to 100% of her base salary. Pfizer said the incentive will be determined based on the salary paid during the year.